moving fast, page-6

Yeah Im not sure these trends are telling us anything new. I say new because this stock has always had considerable insto interest.

Having said that a lot of instos do route their orders through commsecs interface against the exchange. So it could be all insto buying.

Maybe I am overly optomistic but I get the impression that the engagement with FDA has been very good. In view of this I can only see the post TH statement as either being confirmation of new PDFUA date in line with guidance or a miraculous approval decision. The statement does indicate results of the review which means the FDA must of reviewed the modified 022 data to compensate for timestamp issues.